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eligible patients is viewed less negatively in states with more-
restrictive Medicaid coverage.
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OBJECTIVE: To analyse the degree of trust placed in sources
of medical information by practising doctors-therapists.
METHODS: We questioned 144 doctors or therapists from
various cities in Central Russia. Doctors completed a question-
naire containing demographic data, information sources and
how much trust they placed in these sources. RESULTS: Mean
age of respondents was 43.4 [SD 9.8] years with 60% women
and 40% men. Most (92%) noted that their basic sources of
specialised information were various medical magazines. In daily
work, 84% use various directories and consult with colleagues.
Doctors use books and other monographs in 55% of cases and
49.3% receive information from medical representatives of com-
panies. Just over a quarter (29% and 26%) receive information
from advanced training courses and from weekly hospital meet-
ings. Only 1.7% of doctors use specialized medical Internet sites.
The most important criteria for quality information were avail-
ability and reliability of data. The most trustworthy information,
in the opinion of practising doctors, was from medical magazines
(78%) and information from courses to upgrade qualiﬁcations
(60%). CONCLUSION: Our data reﬂect the need to implement
measures to improve the quality of medical information.
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OBJECTIVE: CDR is the Canadian central review agency whose
advisory body, the Canadian Expert Drug Advisory Committee
(CEDAC), makes recommendations for drug reimbursement
decisions by public payers. CEDAC is explicitly charged to con-
sider cost-effectiveness in its mandate. A review was conducted of
all Reasons for Recommendation to determine if and how cost-
effectiveness information was used. METHODS: Reasons for
Recommendation were identiﬁed from the CDR website, from
inception (September 2003) to the end of October 2007. Reasons
were reviewed by both authors. Each drug indication was cat-
egorized as follows: cost-effectiveness was mentioned in the
Reasons, incremental cost-effectiveness ratios (ICERs) were con-
sidered attractive, and the listing recommendation. ICERs were
designated as attractive or not based on either direct comments
in the Reasons or indirectly through the restrictiveness of the
recommended criteria. Descriptive statistics were performed.
RESULTS: There were recommendations for 78 unique drug
submissions. Economic evidence was not mentioned in 55% of
recommendations (N = 44). Costeffectiveness was mentioned in
the remaining 45% of recommendations (N = 34). The ICER
was considered attractive for 15% of drugs (N = 5), with an
ICER range from dominant (N = 3) to $71K/life year gained.
These ﬁve drugs had positive listing recommendations. Drugs
that were economically unattractive but achieved positive recom-
mendations had an ICER range (where stated) from $50K–
$80K/QALY. Economically unattractive drugs with negative rec-
ommendations had an ICER range from $18K to $189K/QALY.
CONCLUSION: Cost-effectiveness was often not mentioned in
CEDAC recommendations. There appeared to be an acceptabil-
ity threshold of $50K/QALY with a grey zone extending up to
$80K/QALY. However, many drugs were not recommended
which had ICERs below these thresholds. Overall, economic
information had a limited role for informing Canadian drug
reimbursement recommendations.
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OBJECTIVE: To study the impact of a model adopted to
improve availability and accessibility to essential drugs and
impact on hospital budget in a super specialty tertiary care hos-
pital. METHODS: The interventions consisted of selection of
limited list of essential medicines (EML) and procurement
through centralized pooled procurement system in 1996–1997,
followed by setting up of Drugs & Therapeutic Committee
(DTC) to review drug expenditure and prescribing pattern in
1998. Analysis of the annual hospital budget, expenditure on
drugs, availability of key drugs, stock-outs, and ABC analysis
was done before (1994–1996) and after intervention (1997–
2004). RESULTS: Rise in average drug expenditure from 3.63%
to 5.16% only was observed after intervention despite 5-fold rise
in patient attendance. Previous trend of ever rising annual drug
expenditure was reversed immediately after interventions in
1997 as drug expenditure reduced by 47%, accompanied by
increased availability (94.6%) of key drugs. Despite high expen-
diture on key drugs (75.89%) mean availability was 67.48%
but after intervention with the same expenditure (77.68%) it
increased to 95.28%. Percent drugs out-of-stock decreased from
27.57% to 19.57% & were of minor duration with no stock-out
of vital drugs. ABC analysis before intervention showed only
3.33 drugs of the category A consumed 74% budget which
increased to 9.63 drugs consuming 79.53% of the annual drug
budget. Analysis of top 10 drugs consumed showed reversal of
previous trend of non-essential among top 10 drugs from 1998
onwards where only vital drugs represented top 10 drugs. CON-
CLUSION: Effective containment of overall expenditure on
drugs accompanied by increased availability of essential drugs is
possible by some managerial interventions-selection of essential
drugs, centralized pooled procurement and functioning DTC.
These interventions serve to optimize the value of limited gov-
ernment funds and thereby empower and support government in
making basic medicines available to all.
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OBJECTIVE: This study used a sample cohort of Medicare-
eligible patients to determine the yearly and regional variation in
estimated annual costs (EAC) of all stand-alone Medicare Part D
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